ZA202404615B - Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer - Google Patents

Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer

Info

Publication number
ZA202404615B
ZA202404615B ZA2024/04615A ZA202404615A ZA202404615B ZA 202404615 B ZA202404615 B ZA 202404615B ZA 2024/04615 A ZA2024/04615 A ZA 2024/04615A ZA 202404615 A ZA202404615 A ZA 202404615A ZA 202404615 B ZA202404615 B ZA 202404615B
Authority
ZA
South Africa
Prior art keywords
inhibitor
treating cancer
methods
dosing regimens
cdk2
Prior art date
Application number
ZA2024/04615A
Other languages
English (en)
Inventor
Lars Anders
Jerry Li
Tun Tun Lin
Todd Lee Vanarsdale
Ping Wei
Jing Yang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA202404615B publication Critical patent/ZA202404615B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2024/04615A 2021-12-02 2024-06-13 Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer ZA202404615B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163285457P 2021-12-02 2021-12-02
PCT/IB2022/061652 WO2023100134A1 (en) 2021-12-02 2022-12-01 Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer

Publications (1)

Publication Number Publication Date
ZA202404615B true ZA202404615B (en) 2025-12-17

Family

ID=84462534

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/04615A ZA202404615B (en) 2021-12-02 2024-06-13 Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer

Country Status (12)

Country Link
US (1) US20250041277A1 (cg-RX-API-DMAC10.html)
EP (1) EP4440575A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024544625A (cg-RX-API-DMAC10.html)
KR (1) KR20240112932A (cg-RX-API-DMAC10.html)
CN (1) CN118647379A (cg-RX-API-DMAC10.html)
AU (2) AU2022402512A1 (cg-RX-API-DMAC10.html)
CA (1) CA3241001A1 (cg-RX-API-DMAC10.html)
IL (1) IL312980A (cg-RX-API-DMAC10.html)
MX (1) MX2024006747A (cg-RX-API-DMAC10.html)
TW (1) TWI873485B (cg-RX-API-DMAC10.html)
WO (1) WO2023100134A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202404615B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
EP4604961A1 (en) * 2022-10-18 2025-08-27 Pfizer Inc. Compounds for the treatment of cancer
EP4719405A1 (en) * 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2025202871A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor
WO2025202854A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
WO2026133192A1 (en) * 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
CN118286225A (zh) 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
CA3128155C (en) 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2

Also Published As

Publication number Publication date
AU2026201311A1 (en) 2026-03-12
IL312980A (en) 2024-07-01
MX2024006747A (es) 2024-06-19
US20250041277A1 (en) 2025-02-06
KR20240112932A (ko) 2024-07-19
TW202332431A (zh) 2023-08-16
TWI873485B (zh) 2025-02-21
WO2023100134A1 (en) 2023-06-08
CA3241001A1 (en) 2023-06-08
CN118647379A (zh) 2024-09-13
EP4440575A1 (en) 2024-10-09
AU2022402512A1 (en) 2024-06-20
JP2024544625A (ja) 2024-12-03

Similar Documents

Publication Publication Date Title
MX2024006747A (es) Metodos y regimenes de dosificacion que comprenden un inhibidor de cinasa 2 dependiente de ciclina (cdk2) y un inhibidor de cinasa 4 dependiente de ciclina (cdk4) para el tratamiento de cancer.
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
CR20200347A (es) Inhibidores pd-1/pd-l1
MX393974B (es) Terapia de combinacion para tratamiento de cancer.
MX2020006963A (es) Composiciones y metodos para tratar anemia.
MX2023011856A (es) Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer.
MX385778B (es) Uso de dianhidrogalactitol y análogos o derivados del mismo para tratar cáncer de células no pequeñas del pulmón y cáncer de ovario.
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
BR112022011998A2 (pt) Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
EA201792650A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
AR048819A1 (es) Metodos sinergicos y composiciones para el tratamiento del cancer
PH12014500869A1 (en) Treatment of cancer with tor kinase inhibitors
MX2010005095A (es) Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion.
MX2022006366A (es) Terapia de combinacion que implica compuestos de diarilo macrociclico.
MX2021013631A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis.
MX2023007850A (es) Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73).
MX2019013862A (es) Terapia de combinacion.
ES2723827T3 (es) Terapia de combinación de fármacos para el tratamiento de tumores sólidos
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
PH12022552347A1 (en) Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
MX2024013787A (es) Inhibidores de menina-mll para el tratamiento de cáncer.
ZA201800787B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
MX2024012392A (es) Terapia combinada para el tratamiento del cancer
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.